Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice
- PMID: 18347211
- DOI: 10.1161/CIRCULATIONAHA.107.745091
Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice
Abstract
Background: Monocytes are critical mediators of atherogenesis. Deletion of individual chemokines or chemokine receptors leads to significant but only partial inhibition of lesion development, whereas deficiency in other signals such as CXCL16 or CCR1 accelerates atherosclerosis. Evidence that particular chemokine pathways may cooperate to promote monocyte accumulation into inflamed tissues, particularly atherosclerotic arteries, is still lacking.
Methods and results: Here, we show that chemokine-mediated signals critically determine the frequency of monocytes in the blood and bone marrow under both noninflammatory and atherosclerotic conditions. Particularly, CCL2-, CX3CR1-, and CCR5-dependent signals differentially alter CD11b(+) Ly6G(-) 7/4(hi) (also known as Ly6C(hi)) and CD11b(+) Ly6G(-) 7/4(lo) (Ly6C(lo)) monocytosis. Combined inhibition of CCL2, CX3CR1, and CCR5 in hypercholesterolemic, atherosclerosis-susceptible apolipoprotein E-deficient mice leads to abrogation of bone marrow monocytosis and to additive reduction in circulating monocytes despite persistent hypercholesterolemia. These effects are associated with a marked and additive 90% reduction in atherosclerosis. Interestingly, lesion size highly correlates with the number of circulating monocytes, particularly the CD11b(+) Ly6G(-) 7/4(lo) subset.
Conclusions: CCL2, CX3CR1, and CCR5 play independent and additive roles in atherogenesis. Signals mediated through these pathways critically determine the frequency of circulating monocyte subsets and thereby account for almost all macrophage accumulation into atherosclerotic arteries.
Similar articles
-
Regulation of monocyte subset systemic levels by distinct chemokine receptors controls post-ischaemic neovascularization.Cardiovasc Res. 2010 Oct 1;88(1):186-95. doi: 10.1093/cvr/cvq153. Epub 2010 May 25. Cardiovasc Res. 2010. PMID: 20501509
-
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques.J Clin Invest. 2007 Jan;117(1):185-94. doi: 10.1172/JCI28549. J Clin Invest. 2007. PMID: 17200718 Free PMC article.
-
Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.Circulation. 2004 Feb 24;109(7):932-7. doi: 10.1161/01.CIR.0000112595.65972.8A. Epub 2004 Feb 2. Circulation. 2004. PMID: 14757698
-
Chemokines in atherosclerosis: an update.Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1897-908. doi: 10.1161/ATVBAHA.107.161174. Epub 2008 Jun 19. Arterioscler Thromb Vasc Biol. 2008. PMID: 18566299 Review.
-
Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker?Clin Chim Acta. 2007 Aug;383(1-2):21-9. doi: 10.1016/j.cca.2007.04.019. Epub 2007 May 3. Clin Chim Acta. 2007. PMID: 17521622 Review.
Cited by
-
Circadian Influence on Metabolism and Inflammation in Atherosclerosis.Circ Res. 2016 Jun 24;119(1):131-41. doi: 10.1161/CIRCRESAHA.116.308034. Circ Res. 2016. PMID: 27340272 Free PMC article. Review.
-
Chemokine (C-C motif) Ligand 2 is a potential biomarker of inflammation & physical fitness in obese children: a cross-sectional study.BMC Pediatr. 2013 Apr 4;13:47. doi: 10.1186/1471-2431-13-47. BMC Pediatr. 2013. PMID: 23557387 Free PMC article.
-
Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis.J Clin Invest. 2012 Sep;122(9):3114-26. doi: 10.1172/JCI61758. Epub 2012 Aug 13. J Clin Invest. 2012. PMID: 22886300 Free PMC article.
-
Gene Deficiency in Activating Fcγ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice.PLoS One. 2013 Jun 21;8(6):e66754. doi: 10.1371/journal.pone.0066754. Print 2013. PLoS One. 2013. PMID: 23805273 Free PMC article.
-
p53 is an important regulator of CCL2 gene expression.Curr Mol Med. 2012 Sep;12(8):929-43. doi: 10.2174/156652412802480844. Curr Mol Med. 2012. PMID: 22804246 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials